Preferred Name |
Naloxegol |
|
Synonyms |
Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)- 17-(2-propenyl)-, (5alpha,6alpha)- AZ13337019 Movantik NALOXEGOL NKTR-118 Naloxegol |
|
Definitions |
A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C97506 |
|
CAS_Registry |
854601-70-0 |
|
code |
C97506 |
|
Concept_In_Subset | ||
Contributing_Source |
FDA |
|
DEFINITION |
A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists. |
|
FDA_UNII_Code |
44T7335BKE |
|
FULL_SYN |
Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)- 17-(2-propenyl)-, (5alpha,6alpha)- AZ13337019 Movantik NALOXEGOL NKTR-118 Naloxegol |
|
Has_Salt_Form | ||
label |
Naloxegol |
|
NCI_Drug_Dictionary_ID |
703418 |
|
PDQ_Closed_Trial_Search_ID |
703418 |
|
PDQ_Open_Trial_Search_ID |
703418 |
|
Preferred_Name |
Naloxegol |
|
prefixIRI |
Thesaurus:C97506 |
|
Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
UMLS_CUI |
C3700399 |
|
subClassOf |